Farah Nabil, Saleem M. First-Line FOLFIRINOX vs Gemcitabine ± Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma: Real-World Treatment Response and Clinicopathologic Predictors from a 2022 Tertiary-Center Cohort. MECOJ [Internet]. 2026 Apr. 19 [cited 2026 May 28];2(2):11-7. Available from: https://scientificsteps-group.com/ojs/ojs3/index.php/mecoj/article/view/191